

# The Diverse World of Bugs Within: How the Microbiome affects Transplantation

Dr. Tessa Andermann, MD, MPH

Infectious Disease Fellow at Stanford University

# Disclosures

The following faculty and planning committee staff have no financial disclosures:

| Name                  | Institution         |
|-----------------------|---------------------|
| Dr. Andermann, MD MPH | Stanford University |
| Steve Spellman, MBS   | CIBMTR              |
| Maria Brown, MT       | CIBMTR              |
| Sheila Moran, RN      | NMDP                |

# Learning objectives

At the conclusion of this session, attendees will be able to:

- Define the microbiome and its function
- Describe how HCT can change the microbiome
- Explain the microbiome's role in HCT
- Identify challenges to and opportunities for microbiome research in HCT patients

# Outline: The Microbiome

1. What it is
2. How we study it
3. How we influence it
4. How it can impact hematopoietic stem cell transplant (HCT) recipients
5. “Microbiome stewardship” in HCT recipients
6. The future of microbiome research

# THE HUMAN MICROBIOME

100 trillion microbes

3% human body mass


1-10X microbes :  
human cells

10-100X microbial :  
human genes

Largest # microbes: GI  
tract




# Human Microbiome





Lee YK, et al. Science 2010.

# Microbiome-Disease Associations



# A Growing Interest in the Microbiome



A microscopic view of various bacteria, including rod-shaped and spherical forms, some with flagella, set against a light blue background. The bacteria are shown in various orientations and sizes, creating a sense of a diverse microbial community.

# **The Evolution of Sequencing to Study the Microbiome**


# 1. Polymerase chain reaction (PCR)

DNA from a single organism isolated from culture

**Primers**




PCR amplification




Sequence of target DNA from one organism


## 2. 16S Ribosomal RNA Sequencing




### 3. Whole Genome Shotgun Metagenomic Sequencing




Bacteria



Viruses



Fungi




Parasites




Fragment DNA




### 3. Whole Genome Shotgun Metagenomic Sequencing




### 3. Whole Genome Shotgun Metagenomic Sequencing



# Next-Generation Sequencing



### 3. Whole Genome Shotgun Metagenomic Sequencing



# Comparison of Sequencing Techniques


## **16S sequencing**

Gross taxonomic classification



## **Metagenomic sequencing + limited gene analysis**

Higher resolution taxonomic classification



## **Metagenomic sequencing + whole genome analysis**


Species/strain level classification

Non-bacterial data


Metabolic pathways




# The Microbiome in HCT




# The Microbiome in HCT



# The Microbiome in HCT



# The Microbiome in HCT




A microscopic view of various bacteria, including rod-shaped and spherical forms, some with flagella, set against a light blue background. The bacteria are shown in various orientations and sizes, creating a sense of a diverse microbial community.


# **How to Impact the Microbiome**

# Microbiome manipulation

## Antibiotics



# Antibiotics and the Microbiome




# Antibiotics and the Microbiome


Antibiotics




1. Alteration in population structure



2. Enrichment for resistance




3. Increased mobilization of genetic elements




4. Availability for niche intrusion

**Antibiotics → Decreased resistance to colonization**

# How Antibiotics Decrease Colonization Resistance




# The Microbiome and the Immune System



GO HAND IN HAND

# Antibiotics Decrease Colonization Resistance




↑ *Enterococcus spp.*




Enterococcus  
bloodstream infection

# Antibiotics Decrease Colonization Resistance





# Antibiotics Decrease Colonization Resistance



# Microbiome manipulation

## Prebiotics




# Prebiotics


- Dietary fibers
- Indigestible by humans
- Nutrition for healthy gut bacteria  
↑ *Bifidobacterium spp.*

Sugars:


● Glucose  
● Fructose




Fructo-oligosaccharides (FOS):




# Prebiotics



Prebiotic →




Fermentation




↑ Short-chain fatty acids  
(SCFAs)


# Short-Chain Fatty Acids (SFCAs)



Acetate



Propionate



Butyrate

- Maintain integrity of intestinal mucosa
- Improve intestinal immune regulation
- ↓ Pro-inflammatory cytokines & immune cells
- ↑ Anti-inflammatory cytokines & immune cells (e.g. T-regs)

# Can Prebiotics Benefit HCT Recipients?

- Observational study of 44 HCT recipients  
(Iyama et al. Case Reports in Oncology, 2014)
  - Fructo-oligosaccharides 9g/day (n=22)\*
  - Controls (n=22)
- FOS vs. controls
  - ↓ Severe diarrhea and mucositis
  - ↓ Weight loss
  - ↑ Overall survival at day +100 (100% vs. 77%,  $p < 0.05$ )

\* FOS plus glutamine


# A Single-Arm Dose-Escalation Trial of FOS

Primary Outcome: Maximum tolerated dose  
Tolerability = 70% or more of doses taken

## Eligibility (n=15)

- $\geq 18$  years of age
- Hematologic malignancy
- Allogeneic HCT
- Reduced-intensity conditioning protocol

## Stool collection



## Treatment (21 days):

FOS 5g, 10g, or 15g per day

\* Blood samples

# Results of trial to date

| FOS dose                        | 5g/day<br>N=5 | 10g/day<br>N=10 | Total<br>N=15 |
|---------------------------------|---------------|-----------------|---------------|
| Consumed $\geq 70\%$ FOS doses* | 4 (80%)       | 6 (60%)         | 10 (66.7%)    |
| Mean % of doses taken           | 81.4%         | 59.1%           | 80%           |

- No serious adverse events
- Minor: flatulence and abdominal discomfort


# Microbiome manipulation

## Probiotics



# Can Probiotics Benefit the Gut Microbiome?


*Lactobacillus rhamnosus* →



↓ Mortality  
↓ GVHD

Allogeneic HCT mouse model

# Can Probiotics Benefit the Gut Microbiome?




Allogeneic HCT mouse model

Mathewson et al. Nature Immunology, 2016

Simms-Waldrup et al. BBMT, 2017

# Can Probiotics Benefit HCT Recipients?

- RCT (n=31)
- *Lactobacillus rhamnosus* →



## No effect:


- Mortality
- GVHD
- No adverse events

Allogeneic HCT recipients

# Fecal Microbiota Transplant (FMT)

Healthy donor stool →

- Nasogastric tube
- Colonoscopy
- Oral “crapsules”



In all patients:

- 70-90% resolution of CDI

In HCT patients:


- 18 patients published
- 16 of 18 resolved CDI
- No adverse events

Recurrent or refractory  
*Clostridium difficile* infection  
(CDI)

Eli Moss, Shannon Falconer et al. PLOS One, 2017

# Fecal Microbiota Transplant (FMT)

Healthy donor stool →




- Resolution of GI GVHD:
- 5 of 7 published cases
  - 2 of 7 partial resolution
  - No adverse events

Steroid-refractory GI GVHD


Kakihana et al. Blood, 2016

Spindelboeck et al. Haematologica, 2017


A microscopic view of various bacteria, including rod-shaped and spherical forms, some with flagella, set against a light blue background. The bacteria are rendered in a semi-transparent, glowing style.

# **How Changes in the Microbiome Can Impact HCT Patients**


# Microbiome Impact:

- 
- 1. Mortality**
  - 2. GVHD**
  - 3. Relapse**

# Microbiome Impact: **Mortality**




# Microbiome Diversity Decreases After Allo-HCT




# Microbiome Diversity at Engraftment

Relative abundance

High Diversity (Inverse Simpson Index  $>4$ )



Low Diversity (Inverse Simpson Index  $<2$ )




## Taxonomy (Genus)




# Microbiome Diversity

High Diversity




# Microbiome Diversity at Engraftment


Low Diversity



# Low Diversity at Engraftment is Associated with Decreased Survival



# Microbiome Impact: **GVHD**

A microscopic image showing a variety of bacteria, including rod-shaped and spherical forms, in shades of green and yellow against a light blue background.

**1. Diversity**

**1. Anaerobic bacteria**

# Microbiome Impact: **GVHD**


## **1. Diversity**




# Low Diversity at Engraftment is Associated with GVHD

↓ Stool microbiota  
diversity at engraftment


↑ Severe acute GVHD



# Diversity Prior to Conditioning is NOT Associated with GVHD




# Donor Diversity IS Associated with GVHD




# Microbiome Impact: **GVHD**

## **2. Anaerobic bacteria**



# Decrease in Obligate Anaerobes Associated with GVHD

## None or minimal anaerobic activity




# Decrease in Obligate Anaerobes Associated with GVHD


- Anti-anaerobic antibiotics associated with ↑ GVHD-related mortality

## None or minimal anaerobic activity

### Aztreonam




### Cefepime




## Significant anaerobic activity

### Imipenem



### Piperacillin-tazobactam




Months After Transplant


— No Antibiotics  
— + Antibiotic

# Decrease in Obligate Anaerobes Associated with GVHD

- Anti-anaerobic antibiotic exposure  $\uparrow$  GVHD
- Greatest association with clindamycin



# Decrease in *Clostridia* spp. Associated with GVHD




\* ↑ Anti-inflammatory *Clostridia* spp. → ↓ GVHD


# Decrease in *Blautia* spp. Associated with GVHD

↓ *Blautia* spp. associated with:

- ↑ GVHD-related mortality
- ↑ Overall mortality
- ↑ Treatment-related mortality
- ↑ Relapse-related mortality




# Microbiome Impact: **Relapse**



# Organisms in the Microbiome are Associated with Relapse

↑ Relative abundance of a bacterial group composed of *Eubacterium limosum*

↓ Relapse of hematologic malignancy



# Take Home Points: The Microbiome in HCT

1. Complex ecosystem of organisms required for human health
2. Disturbances associated with important clinical outcomes
3. The lack of diversity in the intestinal microbiome is associated with worse outcomes
4. Obligate anaerobic bacteria are associated with colonization resistance and improved outcomes

# Microbiome Stewardship in HCT Recipients

- Antibiotics save lives!
- The health cost of antibiotics:
  - To public health → antimicrobial stewardship
    - ↑ Antibiotic resistance



# Microbiome Stewardship in HCT Recipients

- Antibiotics save lives!
- The health cost of antibiotics:
  - To public health → antimicrobial stewardship
    - ↑ Antibiotic resistance
  - To individuals → microbiome stewardship
    - ↑ Antibiotic resistance
    - +
    - ↑ Infection, GVHD, relapse, mortality



# Microbiome Stewardship in Practice



## 1. Febrile neutropenia

Anaerobe-killing (pip-tazo, carbapenems)

vs.

Anaerobe-sparing (cefepime)

→ RCT at MSKCC



# Microbiome Stewardship in Practice


## 2. Gut decontamination:

- Rifaximin vs. fluoroquinolones
  - Better preservation of intestinal microbiome
  - Decreased 1-year mortality
- No antibiotics?

# Future Areas of Research

| Current             | Future                                                  |
|---------------------|---------------------------------------------------------|
| Gastrointestinal    | Non-GI:<br>skin, eye, lung, vagina                      |
| Acute GVHD          | Chronic GVHD                                            |
| 16S rRNA sequencing | Metagenomics,<br>metatranscriptomics,<br>metaproteomics |
| Bacteria            | Bacteria, viruses, fungi,<br>parasites                  |
| Single-institution  | Multi-institutional                                     |
| Association         | Causation                                               |

# Thank you



## Bhatt Lab

**Ami Bhatt**

Karen Andrade

Alex Bishara

Paulina Chemaly

Matt Durant

Brayon Fremin

Joyce Kang

Michelle Li

Jessica Ribado

Hila Sberro

Fiona Tamburini


Katia Tkachenko

Spectrum



**Stanford**  
MEDICINE

*The Stanford Center for Clinical and Translational Research and Education*



**ASBMT™**

American Society for Blood  
and Marrow Transplantation

# Evaluation Reminder

Please complete the Council Meeting 2017 evaluation in order to receive continuing education credits and to provide suggestions for future topics.

We appreciate your feedback!